Free Trial

HC Wainwright Cuts Earnings Estimates for Coya Therapeutics

Coya Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright lowered its FY2026 EPS estimate for Coya Therapeutics to a loss of $1.50 per share from a projected loss of $1.30, while maintaining its Buy rating and $18 price target.
  • Coya reported a quarterly loss of $0.45 per share, missing analysts’ $0.34 loss estimate; revenue of $0.23 million exceeded the $0.11 million consensus.
  • Analyst sentiment is broadly positive but mixed: MarketBeat reports a Moderate Buy consensus and a $15 average price target, with five Buy ratings and one Sell rating.
  • Interested in Coya Therapeutics? Here are five stocks we like better.

Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Analysts at HC Wainwright cut their FY2026 earnings per share estimates for Coya Therapeutics in a research note issued on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($1.50) for the year, down from their prior estimate of ($1.30). HC Wainwright has a "Buy" rating and a $18.00 price target on the stock. The consensus estimate for Coya Therapeutics' current full-year earnings is ($1.53) per share. HC Wainwright also issued estimates for Coya Therapeutics' Q4 2026 earnings at ($0.45) EPS and Q4 2027 earnings at ($0.34) EPS.

Several other equities research analysts have also recently commented on COYA. Chardan Capital reissued a "buy" rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Coya Therapeutics in a research report on Thursday, October 15th. BTIG Research reiterated a "buy" rating and issued a $16.00 target price on shares of Coya Therapeutics in a research note on Tuesday, September 15th. Roth Capital reiterated a "buy" rating and issued a $12.00 target price on shares of Coya Therapeutics in a research note on Monday, August 24th. Finally, Wall Street Zen downgraded shares of Coya Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $15.00.

Check Out Our Latest Stock Report on Coya Therapeutics

Coya Therapeutics Price Performance

COYA opened at $3.13 on Monday. Coya Therapeutics has a fifty-two week low of $2.72 and a fifty-two week high of $6.62. The business has a 50-day moving average of $4.29 and a 200-day moving average of $4.58. The company has a market capitalization of $73.43 million, a PE ratio of -2.25 and a beta of 0.70.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.11). Coya Therapeutics had a negative net margin of 643.44% and a negative return on equity of 71.48%. The firm had revenue of $0.23 million during the quarter, compared to analysts' expectations of $0.11 million.

Institutional Trading of Coya Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP raised its stake in shares of Coya Therapeutics by 29.6% in the 3rd quarter. Marshall Wace LLP now owns 323,849 shares of the company's stock valued at $1,622,000 after acquiring an additional 74,056 shares in the last quarter. Allworth Financial LP lifted its holdings in Coya Therapeutics by 1,200.0% in the 2nd quarter. Allworth Financial LP now owns 13,000 shares of the company's stock worth $76,000 after purchasing an additional 12,000 shares during the last quarter. AXQ Capital LP acquired a new stake in Coya Therapeutics in the 2nd quarter worth approximately $116,000. Long Corridor Asset Management Ltd bought a new stake in Coya Therapeutics during the second quarter worth approximately $227,000. Finally, ADAR1 Capital Management LLC bought a new stake in Coya Therapeutics during the first quarter worth approximately $161,000. Institutional investors and hedge funds own 39.75% of the company's stock.

Coya Therapeutics Company Profile

(Get Free Report)

Coya Therapeutics is a clinical-stage biotechnology company developing therapies that aim to enhance the function of regulatory T cells, immune cells that help control inflammation. Its research focuses on potential treatments for neurodegenerative and other diseases associated with inflammation and immune dysfunction. The company's development programs include biologic and cell-based approaches, with candidates under investigation for conditions including amyotrophic lateral sclerosis (ALS). These therapies remain in development; Coya does not have an approved commercial product.

Read More

Earnings History and Estimates for Coya Therapeutics (NASDAQ:COYA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Coya Therapeutics Right Now?

Before you consider Coya Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.

While Coya Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines